Aldeyra Therapeutics experienced a significant 74% drop in its stock value during premarket trading on Thursday. This drastic decline followed the U.S. Food and Drug Administration’s second rejection of the company’s lead asset, reproxalap. The drug was intended to treat the ophthalmic condition known as dry eye disease. The FDA’s decision marks another setback for Aldeyra, highlighting the challenges pharmaceutical companies face in gaining approval for new therapies.
Died Suddenly
@DiedSuddenly_
·
22h WOW: Moderna & Novavax stocks TANKED over 10% after the FDA’s pro-vaccine Peter Marks resigned under RFK Jr’s leadership.
Big pharma is losing
Camus
@newstart_2024
·
Apr 2 Moderna & Novavax stocks tanked 10%+ after FDA’s Peter Marks, a vax pusher who rammed through COVID vax approval, resigned amid RFK Jr.’s skepticism. Pfizer’s down 2%. Suck it, Big Pharma—your golden boy’s out and the house of cards is crumbling.
Reuters Business
@ReutersBiz
·
Mar 31 Watch: Shares of US drugmakers fell after reports that the FDA’s top vaccine official, Peter Marks, had been forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies https://reut.rs/43S4pNh
Reuters
@Reuters
·
Mar 31 Shares of US drugmakers fell after reports that the FDA’s top vaccine official, Peter Marks, had been forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies https://reut.rs/43S4pNh
Reuters Asia
@ReutersAsia
·
Mar 31 Shares of US drugmakers fell after reports that the FDA’s top vaccine official, Peter Marks, had been forced to resign. This was the most high-profile exit at FDA amid the Trump administration’s overhaul of federal health agencies https://reut.rs/43S4pNh
Adu Subramanian
@plainyogurt21
·
Mar 30 I wrote about regulatory flexibility in December and Peter marks was a key player. I write about his departure and the impact of FDA layoffs now.
TLDR: It’s bad right now. People at the FDA, Investors, and Biopharma Companies face uncertainty. But biotech and the FDA be okay in
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
